Molecular diagnostics firm ChromaCode nets $28 mln Series C

ChromaCode Inc, a molecular diagnostics company, has secured $28 million in Series C financing.

ChromaCode Inc, a molecular diagnostics company, has secured $28 million in Series C financing. Northpond Ventures. In addition to the funding, Pat Smerkers of Northpond has joined ChromaCode’s board of directors.

Source: Press Release